JP2010518088A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518088A5 JP2010518088A5 JP2009549126A JP2009549126A JP2010518088A5 JP 2010518088 A5 JP2010518088 A5 JP 2010518088A5 JP 2009549126 A JP2009549126 A JP 2009549126A JP 2009549126 A JP2009549126 A JP 2009549126A JP 2010518088 A5 JP2010518088 A5 JP 2010518088A5
- Authority
- JP
- Japan
- Prior art keywords
- unit dosage
- picoplatin
- dosage form
- composition
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims description 74
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 70
- 229950005566 picoplatin Drugs 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 57
- 239000002775 capsule Substances 0.000 claims description 34
- 238000009472 formulation Methods 0.000 claims description 21
- 150000001720 carbohydrates Chemical class 0.000 claims description 18
- 235000014633 carbohydrates Nutrition 0.000 claims description 18
- 235000010980 cellulose Nutrition 0.000 claims description 15
- 229920002678 cellulose Polymers 0.000 claims description 15
- 239000001913 cellulose Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 239000002270 dispersing agent Substances 0.000 claims description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 8
- -1 alkaline earth metal salt Chemical class 0.000 claims description 8
- 229920003086 cellulose ether Polymers 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 239000000314 lubricant Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 6
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 229910052697 platinum Inorganic materials 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000011859 microparticle Substances 0.000 claims description 5
- 239000003605 opacifier Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 229910010413 TiO 2 Inorganic materials 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 238000010902 jet-milling Methods 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 150000005846 sugar alcohols Chemical class 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229940057948 magnesium stearate Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88920107P | 2007-02-09 | 2007-02-09 | |
| US88967507P | 2007-02-13 | 2007-02-13 | |
| US98415607P | 2007-10-31 | 2007-10-31 | |
| US98902007P | 2007-11-19 | 2007-11-19 | |
| PCT/US2008/001746 WO2008097658A1 (en) | 2007-02-09 | 2008-02-08 | Encapsulated picoplatin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010518088A JP2010518088A (ja) | 2010-05-27 |
| JP2010518088A5 true JP2010518088A5 (enExample) | 2012-03-29 |
Family
ID=39682045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549126A Pending JP2010518088A (ja) | 2007-02-09 | 2008-02-08 | カプセル化されたピコプラチン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20100062056A1 (enExample) |
| EP (1) | EP2109451A4 (enExample) |
| JP (1) | JP2010518088A (enExample) |
| KR (2) | KR20150125728A (enExample) |
| CN (1) | CN101663040A (enExample) |
| AU (1) | AU2008214199A1 (enExample) |
| BR (1) | BRPI0806362A2 (enExample) |
| CA (1) | CA2677639A1 (enExample) |
| IL (1) | IL200261A0 (enExample) |
| MX (1) | MX2009008487A (enExample) |
| RU (1) | RU2009133447A (enExample) |
| WO (1) | WO2008097658A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| WO2009011861A1 (en) * | 2007-07-16 | 2009-01-22 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
| EP2249644A4 (en) * | 2008-02-08 | 2012-05-30 | Poniard Pharmaceuticals Inc | PICOPLATIN AND AMRUBICIN FOR THE TREATMENT OF LUNG CANCER |
| WO2010120336A1 (en) * | 2009-04-15 | 2010-10-21 | Poniard Pharmaceuticals, Inc. | High bioavailability oral picoplatin anti-cancer therapy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4419340A (en) * | 1969-03-24 | 1983-12-06 | University Of Delaware | Controlled release of anticancer agents from biodegradable polymers |
| US4302446A (en) * | 1979-10-02 | 1981-11-24 | Bristol-Myers Company | Pharmaceutical compositions |
| MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
| JP2657393B2 (ja) * | 1988-05-18 | 1997-09-24 | 日本化薬株式会社 | 化学塞栓療法剤 |
| CN1071570C (zh) * | 1993-06-14 | 2001-09-26 | 詹森药业有限公司 | 阿司咪唑和假麻黄碱的缓释薄膜包衣片 |
| US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| GB9502799D0 (en) * | 1995-02-14 | 1995-04-05 | Johnson Matthey Plc | Improvements in platinum complexes |
| DE19847618A1 (de) * | 1998-10-15 | 2000-04-20 | Basf Ag | Verfahren zur Herstellung von festen Dosierungsformen |
| US6894049B1 (en) * | 2000-10-04 | 2005-05-17 | Anormed, Inc. | Platinum complexes as antitumor agents |
| SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
| CA2456746A1 (en) * | 2001-08-20 | 2003-02-27 | Transave, Inc. | Method for treating lung cancers |
| CN1681478A (zh) * | 2002-08-02 | 2005-10-12 | 川塞夫有限公司 | 铂聚集体及其制备方法 |
| US20060128762A1 (en) * | 2002-09-06 | 2006-06-15 | D.Western Therapeutics Institute | Medicinal composition and method for treating malignant tumor and utilization thereof |
| DE10325989A1 (de) * | 2003-06-07 | 2005-01-05 | Glatt Gmbh | Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung |
| PL1720540T3 (pl) * | 2004-02-18 | 2008-11-28 | Gpc Biotech Ag | Satraplatyna do leczenia odpornych i opornych nowotworów |
| US9061015B2 (en) * | 2004-12-30 | 2015-06-23 | Pierre Fabre Medicament | Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it |
| WO2006090931A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物の抗癌剤との新規併用 |
| WO2006104668A2 (en) * | 2005-03-11 | 2006-10-05 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
| US8143236B2 (en) * | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) * | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| US7687487B2 (en) * | 2007-04-19 | 2010-03-30 | Bionumerik Pharmaceuticals, Inc. | Camptothecin-analog with a novel, “flipped” lactone-stable, E-ring and methods for making and using same |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| WO2009011861A1 (en) * | 2007-07-16 | 2009-01-22 | Poniard Pharmaceuticals, Inc. | Oral formulations for picoplatin |
| EP2249644A4 (en) * | 2008-02-08 | 2012-05-30 | Poniard Pharmaceuticals Inc | PICOPLATIN AND AMRUBICIN FOR THE TREATMENT OF LUNG CANCER |
-
2008
- 2008-02-08 RU RU2009133447/15A patent/RU2009133447A/ru not_active Application Discontinuation
- 2008-02-08 MX MX2009008487A patent/MX2009008487A/es not_active Application Discontinuation
- 2008-02-08 WO PCT/US2008/001746 patent/WO2008097658A1/en not_active Ceased
- 2008-02-08 KR KR1020157030498A patent/KR20150125728A/ko not_active Ceased
- 2008-02-08 KR KR1020097018781A patent/KR20090109130A/ko not_active Ceased
- 2008-02-08 JP JP2009549126A patent/JP2010518088A/ja active Pending
- 2008-02-08 EP EP08725387A patent/EP2109451A4/en not_active Withdrawn
- 2008-02-08 BR BRPI0806362-1A patent/BRPI0806362A2/pt not_active IP Right Cessation
- 2008-02-08 AU AU2008214199A patent/AU2008214199A1/en not_active Abandoned
- 2008-02-08 CN CN200880011347A patent/CN101663040A/zh active Pending
- 2008-02-08 CA CA002677639A patent/CA2677639A1/en not_active Abandoned
-
2009
- 2009-08-05 US US12/536,311 patent/US20100062056A1/en not_active Abandoned
- 2009-08-06 IL IL200261A patent/IL200261A0/en unknown
-
2012
- 2012-09-27 US US13/629,108 patent/US20130202690A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009133447A (ru) | Дозированная форма пикоплатина | |
| JP5783489B2 (ja) | トロスピウムの１日１回剤形 | |
| ES2252875T3 (es) | Forma de dosificacion farmaceutica oral de libeeracion prolongada. | |
| US11931463B2 (en) | All-in-one fixed-dose combination for treating Helicobacter pylori infection | |
| US20110008426A1 (en) | Modified release pharmaceutical compositions comprising mycophenolate and processes thereof | |
| MXPA05001538A (es) | Distribuidor de tipo manguito de endoscopio. | |
| WO2006011159A2 (en) | Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability | |
| KR102381586B1 (ko) | 메살라진의 경구용 약제학적 조성물 | |
| JP2010518089A5 (enExample) | ||
| CN101932322A (zh) | 用于治疗丙型肝炎病毒感染的包含HMG-CoA还原酶抑制剂和胆汁酸的药物组合物 | |
| US20070122481A1 (en) | Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer | |
| EP1680100A1 (en) | Compositions of quaternary ammonium containing bioavailability enhancers | |
| US20130251793A1 (en) | Pharmaceutical composition comprising phentermine and topiramate | |
| US20230364075A1 (en) | Multiparticulate dosage forms comprising deutetrabenazine | |
| KR20080003324A (ko) | 현기증을 저지시키는 환약 형태의 조제물 | |
| JP4221299B2 (ja) | フィルム錠剤製造用リバビリン顆粒 | |
| JP2005535700A (ja) | 一硝酸イソソルビド組成物およびその使用方法 | |
| WO2004089333A2 (en) | A stable benzimidazole formulation | |
| EP3790550A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure | |
| JP2008535920A (ja) | 癌の治療のための、フルオロシチジン誘導体を含む改変放出組成物 | |
| RU123325U1 (ru) | Гранула противотуберкулезного лекарственного средства | |
| KR100505898B1 (ko) | 철분함유 고밀도 펠렛 조성물 및 이의 제조방법 | |
| BR122025009427A2 (pt) | Composições de gama-hidroxibutirato, usos de gama-hidroxibutirato e métodos de preparação das composições e micropartículas de liberação modificada ou imediata de oxibato de sódio |